On July 18, 2023, Human Stem Cell Institute (HSCI, MOEX: ISKJ) announced that it was renamed Artgen Biotech. At the official presentation, the company showed its new corporate identity, logo and informed about the launch of a new website, www.artgen.ru.
The decision to change the name was approved at HSCI’s AGM on June 29, 2023. According to management, the changes have been made to make the company’s activities, strategy, and values clearer to a wide range of investors and the public.”
“We want the society to have a simple and correct understanding of our activities,” comments HSCI’s founder Artur Isaev. “HSCI raised the bar many times and has become more than a stem cells institute. Today, Artgen Biotech is not only a portfolio of developments, but also an ecosystem of biotech companies. As an industry strategist, we develop and implement platform technologies, create new drugs, medical devices and services in state-of-the-art areas of biomedicine, increasing the efficiency of healthcare. In the long run, this will allow us to ensure high returns on capital. It is important for us and our investors that we do not just conduct research and develop technologies, but increase the efficiency of healthcare, contribute to the fight against diseases, and develop Russia’s biotech industry.”
Background information:
Artgen Biotech is a biotechnology company whose goal is to create, develop, and implement in medical practice innovative drugs, devices or treatment, diagnostics, and prevention methods that provide new means to combat human diseases that are more effective than the existing ones. The group includes companies at different development stages: from seed to early growth and maturity. The company is solving pressing problems for society and people. Artgen Biotech’s high-tech and innovative developments are aimed at combating socially significant and orphan diseases.
Artgen is a strategic investor in industries that improve the efficiency and quality of medical care. The Company is developing an internal ecosystem to accelerate the group’s biotech companies and commercialize their developments.
The company was founded in 2003. Since 2009, it has been an issuer at the Moscow Exchange Innovation and Investment Market.